Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) reported its first-half 2026 financial results, revealing a notable increase in revenue and a swing to net income, while simultaneously advancing an expanded clinical manufacturing program with a U.S.-based biopharmaceutical company. The company, which combines therapeutic development with a revenue-generating contract development and manufacturing organization (CDMO), is positioning itself to capitalize on growing demand for specialized biopharmaceutical services.
For the first half of 2026, Scinai reported revenue of $949,000, up from $773,000 in the prior-year period. More significantly, committed customer orders reached approximately $3.1 million as of Aug. 16, 2026, including about $2.1 million already invoiced. This growth underscores the company's ability to secure recurring business in the competitive CDMO market. Additionally, Scinai is pursuing approximately $5 million in CDMO revenue for the full year 2026, indicating strong momentum and a clear trajectory for expansion.
In a key development, Scinai is advancing an expanded clinical manufacturing and chemistry, manufacturing and controls (CMC) program for a U.S.-based biopharmaceutical company. The company has received approximately $650,000 in cash payments and advances, with substantive activities already underway, even as a definitive agreement remains under negotiation. The program is intended to support an investigational drug product toward a U.S. investigational new drug (IND) submission and Phase III clinical development. This collaboration highlights Scinai's capability to provide end-to-end services that are critical for biopharmaceutical companies aiming to bring new therapies to market.
Financially, Scinai reported an operating loss of approximately $4.6 million for the first half of 2026, compared with $3.8 million in the same period last year. However, the company achieved net income of approximately $1.6 million, a dramatic improvement from a net loss of approximately $4.1 million in the prior-year period. This positive result was primarily driven by a $6.4 million bargain purchase gain associated with the acquisition of Recipharm Israel, which has added manufacturing capabilities and expanded the company's service offerings.
Cash, cash equivalents, and restricted cash totaled approximately $2.9 million as of June 30, 2026. While this provides a foundation for ongoing operations, the company's ability to secure additional revenue through its CDMO services and advance its therapeutic pipeline will be critical for long-term sustainability.
Scinai continues to advance its PC111 and NanoAbs therapeutic programs, which are part of its broader pipeline of immunology therapies licensed from the Max Planck Society and PinCell S.r.l. The company also owns Scinai Biopharma Services Ltd., a CDMO with facilities in Jerusalem and Yavne, Israel. These assets position Scinai uniquely in the biopharmaceutical landscape, offering both innovative drug development and manufacturing services that can be leveraged for growth.
The announcement comes at a time when the biopharmaceutical industry is increasingly outsourcing manufacturing and development services to specialized CDMOs, driven by the need for cost efficiency and expertise. Scinai's expanded U.S. program is a testament to the growing demand for such services and the company's ability to meet rigorous regulatory standards. The successful execution of this program could lead to additional contracts and reinforce Scinai's reputation as a reliable partner for clinical-stage biopharmaceutical companies.
Investors and industry observers will be watching closely as Scinai finalizes the definitive agreement for the U.S. program and continues to pursue its revenue targets. The company's ability to convert its pipeline of opportunities into long-term, high-value contracts will be key to its future performance. With a strategic focus on both therapeutic innovation and manufacturing services, Scinai is positioning itself to play a significant role in the evolving biopharmaceutical ecosystem.
